While the intrinsic resistance in AML FLT3–directed inhibitors depends on the presence of cooccurring mutations (5), acquired resistance is due to activation of parallel survival pathways and/or acquisition of secondary mutations in FLT3ITD (2, 3, 9). This evidence concerns the gene FLT3 and acute myeloid leukemia.